Nebenwirkungen · Caelyx pegylated liposomal
Caelyx pegylated liposomal 2 mg/ml concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 14
HOS-085580 · Präparat HOS-083155
Cardiac toxicity An increased incidence of congestive heart failure is associated with doxorubicin therapy at cumulative lifetime doses > 450 mg/m2 or at lower doses for patients with cardiac risk factors. Endomyocardial biopsies on nine of ten AIDS-KS patients receiving cumulative doses of Caelyx pegylated liposomal greater than 460 mg/m2 indicate no evidence of anthracycline-induced cardiomyopathy. The recommended dose of Caelyx pegylated liposomal for AIDS-KS patients is 20 mg/m2 every two-to-three weeks. The cumulative dose at which cardiotoxicity would become a concern for these AIDS-KS patients (> 400 mg/m2) would require more than 20 courses of Caelyx pegylated liposomal therapy over 40 to 60 weeks.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-04-24T17:56:00Z · SHA-256 c7886f3f50305fcb29bfb2c8de51dd65f782908ce31d2fdd422d43a9ccecfc7e · Passage fa8ad7b78adbc22c6e3a88106ae3c81e148652d2da497b7cd829ef46bd47e1d4 · Zeichen 14787–15502 im Abschnitt